Integrative interpretable learning reveals shared patterns of epitranscriptomic regulation across multiple cancer types.

Authors

Xiangyu Yin, Gang Tu, Xuan Wang, Yuqi Liu, Yue Wang, Jiongming Ma, XiaoXuan Yu, Jia Meng, Bowen Song

Published in

BMC biology. Volume 24. Issue 1. May 19, 2026. Epub May 19, 2026.

Abstract

Cancer is a complex set of diseases caused by the dysregulation of cell proliferation, differentiation, and apoptosis, ultimately leading to malignant tumor development and metastasis. Recent studies have revealed that dysregulation of N4-acetylcytidine (ac⁴C) acetylation is associated with enhanced metastatic potential and tumor progression in various cancer types. However, it remains unclear whether diverse cancer types share common epitranscriptomic regulatory patterns or engage in interconnected networks.
In this study, leveraging an extensive collection of 88 ac⁴C epitranscriptome datasets profiled across multiple cancer types and normal conditions, we developed the first ac⁴C pan-cancer model by integrating a diverse set of sequence and curated genome-derived knowledge, based on a combined deep learning-powered transformer architecture. Our interpretable analysis uncovered, for the first time, the shared epitranscriptomic patterns and associations of dysregulated ac⁴C across different cancers, particularly associated with low GC-content regions of the 3'UTR and internal 3'UTR splicing. Furthermore, we discovered a set of candidate ac⁴C-mediated genes that may function in cancers through epitranscriptomic regulation, including three novel ac⁴C-mediated candidates (SMARCD1, SENP5, RNF207) that exhibit consistently dysregulated ac⁴C levels, expression patterns, and are associated with poor clinical prognosis across different cancer types.
Taken together, our findings highlight the importance of a comprehensive characterization of ac⁴C epitranscriptome in pan-cancer landscape, with potential implications for developing RNA modification-based biomarkers and therapeutic strategies.

PMID:
42157158
Bibliographic data and abstract were imported from PubMed on 17 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.